In view of the array of symptoms, the patient was referred for medical evaluation of a suspected pheochromocytoma, a neuroendocrine tumor of the adrenal gland. He underwent 24-hour blood pressure ...
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...
A pheochromocytoma is a tumor that produces adrenaline. Adrenaline is commonly associated with the "flight or fight" response. It most commonly originates from cells in the adrenal gland, but can, in ...
A pheochromocytoma is a paraganglioma that arises in adrenal gland tissue, which results in the overproduction of adrenal hormones (epinephrine and norepinephrine). People with familial paranganglioma ...
The US Food and Drug Administration (FDA) has accepted for priority review a supplemental new drug application (sNDA) for ...
The US Food and Drug Administration (FDA) will soon decide on whether to expand the label of MSD’s Welireg (belzutifan) to ...
Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...
The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic ...
Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its Welireg oral cancer drug in patients with rare tumors that form in and around the ...
The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback